First, high-grade ir-AEs of grade 3 and 4 are known to occur significantly more frequently in melanoma patients on dual CPI of ipilimumab and nivolumab (58%) than in those receiving anti-PD1 monotherapy (23%) (19). This evidence concerns the gene PDCD1 and melanoma.